acut
respiratori
distress
syndrom
ard
common
among
mechan
ventil
children
accompani
pediatr
intens
care
unit
death
though
ard
diagnosi
base
clinic
criteria
biolog
marker
acut
lung
damag
extens
studi
adult
children
biomark
inflamm
alveolar
epitheli
capillari
endotheli
disrupt
disord
coagul
associ
derang
measur
circul
bodi
fluid
bronchoalveolar
lavag
improv
understand
pathobiolog
ard
biochem
signatur
ard
increasingli
well
describ
adult
popul
led
identif
molecular
phenotyp
augment
clinic
classif
howev
pauciti
data
pediatr
ard
pard
patient
biomark
molecular
phenotyp
potenti
identifi
patient
high
risk
poor
outcom
perhap
inform
develop
target
therapi
specif
group
patient
addit
lower
incid
mortal
ard
pediatr
patient
rel
adult
lack
robust
clinic
predictor
outcom
ongo
interest
biolog
marker
surrog
outcom
measur
recent
definit
pard
provid
addit
impetu
measur
establish
novel
biomark
futur
pediatr
studi
order
character
diseas
process
chapter
review
current
avail
literatur
discuss
potenti
futur
direct
investig
biomark
ard
among
children
base
prior
definit
clinic
ard
character
noncardiogen
pulmonari
edema
result
hypoxemia
infiltr
chest
radiographi
histopatholog
ard
character
dysregul
lung
inflamm
proteinrich
interstiti
alveolar
edema
consequ
enhanc
permeabl
disrupt
alveolarcapillari
barrier
disrupt
alveolarcapillari
barrier
therebi
lead
protein
leak
transmigr
solubl
protein
biolog
mediat
system
circul
grow
literatur
result
interest
studi
biolog
marker
acut
lung
diseas
includ
ard
plasma
serum
well
bronchoalveolar
lavag
bal
fluid
hope
better
elucid
pathophysiolog
mechan
ali
identifi
potenti
marker
sever
outcom
vast
major
investig
involv
adult
patient
find
subsequ
extrapol
children
larg
pediatr
studi
infrequ
limit
find
small
number
ard
patient
heterogen
underli
diseas
process
lead
pard
overal
low
mortal
pard
multipl
clinic
outcom
predictor
pard
identifi
find
indic
sever
oxygen
defect
dead
space
fraction
organ
failur
underli
immunodefici
import
factor
howev
util
clinic
predictor
limit
rel
low
decreas
rate
mortal
pard
addit
clinic
predictor
may
less
specif
ard
molecular
marker
yet
led
develop
novel
therapi
target
specif
patient
group
therefor
addit
clinic
find
ongo
interest
use
biomark
specif
endotheli
epitheli
integrityinjuri
coagul
fibrinolysi
inflamm
inflammationassoci
cellular
derang
surrog
marker
patient
outcom
pard
main
focu
review
assess
current
knowledg
biomark
pattern
acut
lung
diseaseinjuri
associ
patient
outcom
specif
focu
pediatr
neonat
patient
popul
protein
biomark
measur
blood
bal
fluid
report
literatur
potenti
serv
biolog
marker
present
systemat
manner
base
pathogenesi
inflamm
coagul
epitheli
endotheli
surfact
nonprotein
marker
plasma
serum
biomark
favor
mani
instanc
biomark
bal
fluid
due
rel
easi
avail
blood
sampl
addit
mani
instanc
unstabl
patient
lung
injuri
may
toler
bal
procedur
plasma
serum
biomark
studi
pediatr
neonat
popul
present
tabl
bal
fluid
marker
tabl
biomark
studi
date
proteinbas
also
discuss
sever
nonprotein
biomark
group
potenti
add
understand
pard
intens
studi
protein
biomark
critic
ill
belong
larg
famili
inflammatori
cytokin
dub
interleukin
il
mani
member
famili
studi
form
critic
ill
recogn
ard
risk
factor
sepsi
trauma
postop
state
antagonist
receptor
antagonist
found
bal
fluid
correl
ard
sever
outcom
adult
children
correl
ard
though
significantli
elev
among
cohort
children
sever
acut
respiratori
syndrom
sar
anoth
import
inflammatori
cytokin
elev
plasma
bal
fluid
level
associ
ard
adult
well
plasma
children
neonat
rd
studi
children
burnrel
inhal
injuri
sever
influenza
level
associ
increas
mortal
agreement
adult
data
level
bal
fluid
also
found
elev
prematur
babi
rd
correl
develop
chronic
lung
diseas
cld
biomark
respons
therapi
recent
found
decreas
respons
glucocorticoid
gc
therapi
random
trial
gc
therapi
children
relationship
inflammatori
cytokin
respons
ventil
strategi
also
demonstr
landmark
ardsnet
trial
lowtidalvolum
ventil
level
observ
decreas
lowtidalvolum
group
compar
control
anoth
inflammatori
cytokin
elev
plasma
bal
fluid
adult
ard
associ
organ
failur
mortal
adult
children
ard
rd
plasma
bal
fluid
level
elev
relationship
outcom
remain
less
clear
howev
cohort
includ
critic
ill
children
influenza
ard
preval
nonsurvivor
dramat
higher
plasma
concentr
survivor
suggest
possibl
role
prognost
factor
pard
gener
major
antiinflammatori
cytokin
elev
plasma
bal
fluid
associ
develop
ard
well
ard
mortal
adult
appear
earli
rise
onset
ard
follow
normal
level
first
day
ill
pattern
also
seen
children
ard
without
steroid
therapi
elev
newborn
rd
independ
gestat
age
also
associ
increas
develop
ard
increas
mortal
among
pediatr
burn
patient
inhal
injuri
sever
cytokin
il
famili
includ
pediatr
burn
patient
rd
pard
associ
outcom
lung
injuri
individu
studi
compar
nonsurvivor
survivor
previous
mention
cohort
sever
influenza
patient
investig
also
found
signific
elev
granulocytemacrophag
colonystimul
factor
interferoninduc
protein
monocyt
chemotact
protein
macrophag
inflammatori
protein
though
find
yet
reproduc
pediatr
cohort
tumor
necrosi
factor
alpha
solubl
receptor
divers
effect
immun
system
associ
ard
develop
outcom
adult
role
tnfrelat
activ
pard
less
clear
studi
healthi
neonat
subject
mechan
ventil
found
increas
tracheal
aspir
fluid
plasma
level
correl
cytokin
level
includ
among
children
random
control
trial
corticosteroid
ard
suggest
possibl
role
pard
anoth
group
inflammationrel
protein
signific
interest
matrix
metalloproteinas
mmp
famili
activ
breakdown
remodel
tissu
matric
protein
may
direct
function
signific
addit
util
biomark
mmp
produc
multipl
cell
type
includ
immun
cell
fibroblast
epitheli
cell
mani
differ
subgroup
mmp
identifi
classifi
base
substrat
sever
studi
found
associ
level
mmp
antagonist
tissu
inhibitor
metalloproteinas
outcom
sepsi
adult
one
studi
mix
popul
ventil
adult
found
serum
level
associ
decreas
surviv
increas
sever
hypoxemia
pediatr
patient
substanti
evid
base
role
mmp
lung
injuri
ard
two
differ
group
demonstr
elev
level
bal
fluid
preterm
babi
rd
found
higher
amount
associ
progress
rd
cld
bronchoalveolar
dysplasia
bpd
one
group
also
identifi
imbal
inhibitor
bal
fluid
lower
level
associ
hypoxemia
prolong
ventil
pard
patient
two
recent
report
describ
elev
bal
fluid
level
ard
patient
rel
control
well
associ
two
protein
need
prolong
mechan
ventil
one
studi
also
examin
relationship
mmp
neutrophilderiv
proteinas
human
neutrophil
elastas
hne
myeloperoxidas
mpo
find
posit
relationship
may
indic
neutrophil
activ
major
sourc
mmp
elev
seen
ard
creactiv
protein
crp
typic
highli
elev
use
marker
acut
inflammatori
state
found
invers
associ
mortal
adult
ard
popul
howev
subsequ
studi
ventil
pediatr
patient
ali
investig
found
higher
crp
level
drawn
within
h
ali
diagnosi
associ
mortal
fewer
ventilatorfre
day
vfd
discord
find
must
interpret
context
multipl
potenti
confound
influenc
two
studi
also
serv
highlight
level
variabl
seen
result
biomark
studi
promot
cautiou
approach
implement
clinic
decis
base
though
mani
inflammatori
cytokin
studi
pard
singl
one
demonstr
clear
superior
other
singl
marker
diseas
process
intens
studi
perhap
combin
cytokin
may
offer
complet
pictur
inflammatori
process
activ
pard
mani
molecul
also
specif
inhibitor
offer
entic
prospect
new
treatment
modal
classic
patholog
descript
ard
alveolar
space
fill
proteinac
complex
form
characterist
hyalin
membran
complex
compos
larg
part
fibrin
fibrin
breakdown
product
addit
pulmonari
edema
fluid
inflammatori
infiltr
suggest
role
disord
coagul
homeostasi
ard
relat
condit
preclin
model
support
role
pulmonari
coagulopathi
patholog
mechan
ali
derang
typic
measur
function
coagul
system
prothrombin
time
pt
activ
thromboplastin
time
aptt
associ
increas
mortal
organ
failur
children
ard
platelet
also
critic
function
coagul
system
dysregul
ard
thrombocytopenia
ard
onset
report
correl
increas
morbid
mortal
adult
children
howev
addit
familiar
marker
coagul
multipl
novel
biomark
evalu
children
ard
plasminogen
activ
inhibitor
antifibrinolyt
enzym
activ
set
inflamm
depress
fibrinolyt
activ
demonstr
elev
level
bal
fluid
blood
adult
ard
associ
increas
mortal
decreas
vfd
also
evalu
marker
pediatr
patient
among
cohort
pediatr
patient
ard
elev
plasma
also
associ
increas
mortal
decreas
vfd
among
cohort
critic
ill
children
level
bal
fluid
also
abl
discrimin
patient
ventilatorassoci
pneumonia
vap
compar
colon
patient
plasma
level
significantli
elev
patient
septic
shock
purpura
ard
addit
anoth
import
regul
coagul
activ
lung
diseas
solubl
urokinasetyp
plasminogen
activ
receptor
supar
protein
bind
urokinas
upa
cell
surfac
facilit
proteolyt
activ
plasminogen
proupa
solubl
form
may
addit
role
inflamm
plasma
supar
level
elev
larg
studi
critic
ill
ventil
adult
associ
mortal
neonat
studi
blood
supar
level
elev
among
develop
bpd
compar
control
correl
diseas
sever
similarli
supar
level
shown
correl
sever
cohort
children
pneumonia
though
none
cohort
develop
ard
decreas
plasma
level
antithrombiniii
mediat
heparin
anticoagul
effect
earli
cours
ard
also
associ
increas
mortal
adult
children
though
protein
c
import
regul
activ
thrombin
investig
biomark
therapeut
agent
form
activ
protein
c
apc
adult
ard
patient
addit
studi
need
clarifi
role
children
ard
investig
biomark
coagul
fibrinolysi
pathway
includ
role
tissu
factor
tf
pathway
inhibitor
tfpi
may
advanc
understand
pathogenesi
ard
children
provid
new
therapeut
target
disturb
coagul
fibrinolysi
set
pard
import
pathogenesi
diseas
especi
relat
function
microcircul
develop
organ
failur
supar
pathway
evid
children
dynam
complet
understand
coagul
pathway
critic
improv
outcom
children
pulmonari
alveolar
bronchial
epithelium
integr
compon
alveolarcapillari
barrier
disrupt
ard
may
site
primari
injuri
direct
lung
injurymedi
ard
may
becom
injur
secondarili
result
indirect
mechan
lung
injuri
marker
epitheli
cell
injuri
use
indic
sever
lung
injuri
well
purpos
differenti
patient
differ
mechan
injuri
glycoprotein
highli
associ
epitheli
cell
damag
increas
permeabl
kreb
von
den
present
alveolar
type
ii
pneumocyt
releas
serum
alveolar
line
fluid
elev
level
blood
bal
fluid
associ
develop
ard
well
wors
ard
outcom
adult
patient
studi
children
ard
compar
sepsi
traumat
brain
injuri
serum
elev
ard
patient
higher
level
associ
increas
mortal
studi
level
also
correl
measur
oxygen
length
ventil
lo
pediatr
studi
demonstr
elev
serum
infant
bronchiol
bpd
well
respiratori
complic
sever
development
disabl
children
pediatr
interstiti
lung
diseas
clara
also
known
club
cell
secretori
protein
protein
produc
secret
clara
cell
tracheobronchi
tree
identifi
marker
respiratori
epitheli
injuri
elev
plasma
level
adult
patient
associ
develop
ard
well
increas
mortal
organ
failur
score
compar
control
howev
ware
et
al
compar
level
patient
ali
cardiogen
pulmonari
edema
found
ali
patient
compar
lower
bal
fluid
plasma
level
suggest
elev
may
specif
ard
children
studi
primarili
biomark
neonat
rd
develop
bpd
howev
result
conflict
report
cord
blood
postnat
serum
found
lower
level
patient
went
develop
bpd
one
studi
demonstr
elev
postnat
serum
level
mechan
ventil
infant
correl
progress
bpd
yet
anoth
studi
tracheal
aspir
preterm
infant
show
instead
correl
gestat
age
well
elev
set
acut
infect
though
signific
interest
biomark
potenti
therapi
evid
continu
inconsist
studi
larger
popul
need
solubl
receptor
advanc
glycat
end
product
srage
protein
preferenti
express
basolater
membran
alveolar
type
cell
predomin
epitheli
surfac
cell
lung
adult
studi
shown
elev
plasma
bal
fluid
srage
ard
elev
plasma
srage
correl
increas
mortal
organ
failur
reduc
alveolar
fluid
clearanc
pediatr
studi
demonstr
increas
plasma
srage
patient
bronchiol
rd
plasma
srage
pediatr
postop
cardiac
surgeri
patient
associ
develop
ali
well
wors
oxygen
longer
period
mechan
ventil
note
bal
fluid
srage
level
may
vari
invers
age
account
futur
studi
though
variat
report
plasma
srage
alveolarcapillari
barrier
also
maintain
part
cellular
adhes
molecul
one
protein
becom
establish
import
marker
epitheli
endotheli
integr
solubl
intercellular
adhes
molecul
adult
multipl
studi
associ
blood
bal
fluid
level
develop
ard
well
ard
outcom
mortal
find
confirm
studi
children
first
flori
et
al
describ
increas
mortal
children
ard
independ
associ
elev
sicam
earli
diseas
cours
especi
level
ngml
reproduc
children
ard
receiv
high
frequenc
oscil
ventil
elev
seen
patient
respond
lung
recruit
maneuv
recent
studi
also
demonstr
earli
increas
level
children
ali
compar
control
found
associ
level
durat
ventil
mortal
sicam
studi
tracheal
aspir
infant
rd
concentr
significantli
higher
went
develop
cld
find
highli
consist
underscor
import
adhes
molecul
pulmonari
alveolarcapillari
barrier
pathogenesi
pediatr
lung
injuri
marker
relat
integr
pulmonari
epithelium
strong
associ
outcom
measur
diseas
sever
pard
srage
sicam
exampl
protein
specif
epithelium
shown
promis
biomark
may
prove
use
character
subpopul
children
sever
epitheli
injuri
endothelium
repres
intern
side
alveolarcapillari
barrier
studi
extens
mediat
multipl
diseas
state
includ
sepsi
ard
pulmonari
endotheli
cell
ec
risk
injuri
multipl
potenti
sourc
transmit
extern
sourc
pulmonari
epithelium
well
intern
sourc
system
circul
endotheli
damag
dysfunct
thought
major
mechan
develop
multiorgan
dysfunct
characterist
sever
ard
endothelium
multipl
activ
role
includ
product
adhes
molecul
cytokin
modul
vascular
tone
manag
intravascular
coagul
sever
protein
biomark
studi
surrog
marker
endotheli
injuri
increas
permeabl
von
willebrand
factor
vwf
protein
involv
platelet
function
produc
ec
releas
blood
upon
activ
damag
elev
plasma
children
ard
earli
elev
correl
mortal
decreas
vfd
result
consist
previou
find
infant
rd
well
multipl
adult
studi
solubl
eselectin
endotheli
leukocyt
adhes
protein
upregul
condit
inflamm
eselectin
level
associ
ard
adult
recent
studi
report
elev
plasma
eselectin
level
children
ard
compar
control
well
associ
mortal
among
infant
rd
plasma
eselectin
level
associ
develop
bpd
found
decreas
dexamethason
therapi
lselectin
anoth
member
selectin
famili
leukocyt
adhes
molecul
express
primarili
leukocyt
consist
studi
adult
lselectin
level
plasma
infant
rd
decreas
among
patient
develop
bpd
level
bal
fluid
increas
suggest
possibl
transmigr
leukocyt
alveolar
space
vascular
endotheli
growth
factor
vegf
promot
endotheli
vascular
growth
also
evalu
neonat
rd
found
decreas
concentr
patient
sever
rd
solubl
receptor
svegfr
increas
correl
bal
fluid
vegf
level
diseas
incid
sever
identifi
studi
infant
rd
bpd
anoth
protein
produc
pulmonari
endothelium
well
cell
type
includ
epithelium
smooth
muscl
immun
cell
endothelin
garner
interest
ard
investig
due
pleiotrop
effect
includ
potent
pulmonari
vasoconstrict
stimul
inflammatori
respons
level
examin
two
pediatr
studi
one
neonat
one
children
neonat
group
show
higher
cord
blood
level
infant
rd
control
level
correl
longer
durat
mechan
ventil
studi
children
ard
demonstr
earli
elev
affect
children
compar
control
also
found
signific
associ
level
first
h
diseas
surviv
find
consist
limit
data
plasma
bal
level
adult
ard
patient
research
may
help
guid
futur
investig
potenti
et
antagonist
inhal
nitric
oxid
therapi
ard
patient
solubl
thrombomodulin
stm
circul
protein
form
result
proteolyt
cleavag
cellular
thrombomodulin
membran
bound
protein
involv
coagul
inflammatori
pathway
identifi
marker
endotheli
injuri
group
found
signific
relationship
earli
elev
plasma
stm
organ
failur
larg
pard
cohort
stm
predict
mortal
subset
patient
indirect
mechan
lung
injuri
find
consist
previou
result
group
adult
patient
ard
may
hint
potenti
opportun
endotheli
function
replac
use
recombin
thrombomodulin
increasingli
use
case
sepsi
critic
coagulopathi
mediat
vascular
permeabl
may
play
signific
role
develop
outcom
ard
adult
ard
level
plasma
elev
compar
control
predict
mortal
medic
traumarel
ard
though
data
remain
rel
spars
among
pediatr
patient
recent
report
elev
associ
mortal
pard
addit
rise
level
highli
predict
mortal
among
hematopoiet
stem
cell
transplant
recipi
endothelium
divers
function
involv
among
other
inflamm
coagul
hemodynam
central
role
pathobiolog
ard
children
marker
vwf
selectin
stm
associ
endothelium
ard
differ
function
implic
clinic
assess
marker
help
construct
complet
view
endotheli
function
guid
futur
therapeut
trial
surfact
protein
group
protein
produc
alveolar
type
ii
cell
within
lung
secret
part
complex
substanc
call
pulmonari
surfact
serv
primarili
reduc
surfac
tension
lung
alter
damag
pulmonari
surfact
system
propos
mechan
chang
pulmonari
physiolog
seen
ard
sever
studi
examin
surfact
protein
level
pediatr
patient
lung
injuri
one
larg
studi
examin
children
respiratori
failur
requir
intub
found
lower
level
tracheal
aspir
surfact
protein
spa
surfact
protein
b
spb
rel
total
aspir
fluid
protein
pneumonia
ard
patient
compar
control
spa
level
also
correl
pulmonari
complianc
anoth
smaller
studi
also
found
decreas
normal
level
spa
spb
bal
fluid
children
ard
surfact
protein
spd
found
elev
amount
increas
breakdown
product
studi
also
evalu
plasma
sp
level
find
three
sp
b
elev
plasma
time
ard
diagnosi
plasma
spb
independ
associ
lo
durat
mechan
ventil
elev
bal
fluid
spd
level
also
found
children
vap
compar
ventil
control
plasma
spd
level
also
higher
children
bronchopneumonia
associ
increas
need
supplement
oxygen
similar
find
decreas
level
spa
spb
bal
fluid
report
studi
infant
sever
bronchiol
contrast
report
spd
also
reduc
howev
spd
serum
elev
two
studi
viral
bronchiol
aggreg
result
seem
suggest
rel
deplet
pulmonari
surfact
protein
concomit
increas
plasma
concentr
may
relat
increas
permeabl
alveolarcapillari
barrier
thu
plasma
bal
fluid
surfact
concentr
signific
potenti
biomark
specif
intrapulmonari
process
though
trial
surfact
replac
pard
mix
result
clearli
disrupt
normal
surfact
system
diseas
level
specif
surfact
protein
bal
fluid
blood
associ
clinic
outcom
assess
marker
futur
trial
could
use
stratifi
risk
may
inform
specif
replac
therapi
though
vast
major
biomark
data
avail
pediatr
fall
one
categori
sever
known
marker
fit
easili
btype
formerli
known
braintyp
natriuret
peptid
bnp
probnp
protein
commonli
use
assess
fluid
statu
cardiac
strain
congest
heart
failur
pulmonari
hypertens
among
other
studi
adult
found
bnp
help
discrimin
ard
cardiogen
pulmonari
edema
higher
bnp
level
associ
mortal
similarli
cohort
children
ali
elev
bnp
level
earli
diseas
cours
associ
wors
oxygen
fewer
vfd
increas
need
inotrop
significantli
elev
among
nonsurvivor
find
suggest
bnp
possibl
marker
alter
cardiopulmonari
interact
occur
set
ali
children
marker
limit
evid
children
lung
injuri
includ
solubl
fa
ligand
sfasl
involv
process
program
cell
death
elev
among
infant
rsv
bronchiol
compar
control
though
data
support
role
solubl
fa
sfasl
adult
ard
util
two
marker
pard
remain
unclear
though
much
investig
devot
identif
biomark
ard
focus
protein
great
deal
progress
also
made
area
nonprotein
biomark
nonprotein
marker
quit
vari
gener
categor
lipidbas
molecul
nucleic
acid
microparticl
mp
extracellular
complex
discuss
categori
briefli
lipid
biomark
compris
heterogen
group
hydrophob
molecul
multipl
vari
role
normal
bodili
function
one
group
investig
detail
set
ard
eicosanoid
gener
metabol
fatti
acid
arachidon
acid
includ
prostaglandin
pg
leukotrien
lt
thromboxan
txa
other
mani
potenti
effect
involv
vascular
endotheli
platelet
leukocyt
function
thromboxan
prostacyclin
also
known
prostaglandin
produc
lung
effect
pulmonari
vascular
resist
promot
pulmonari
vasoconstrict
vasodil
sever
studi
risk
adult
txa
level
elev
patient
develop
ard
txa
prostaglandin
ratio
inde
elev
bal
fluid
txa
activ
metabolit
associ
progress
bpd
infant
lung
inflamm
rd
elev
seem
benefici
relationship
earli
studi
rd
also
report
elev
plasma
prostaglandin
e
pge
prostaglandin
f
pgf
low
pge
pgf
ratio
elev
level
lt
detect
blood
bal
fluid
adult
patient
ard
leukotrien
associ
mortal
children
molecul
larg
studi
set
neonat
rd
develop
bpd
elev
urinari
leukotrien
associ
ard
adult
develop
bpd
infant
though
variat
observ
may
highli
affect
gestat
age
matur
sever
studi
neonat
demonstr
alter
level
marker
oxid
stress
dna
damag
rd
one
studi
bal
fluid
children
ali
found
alter
concentr
multipl
cell
surfac
lipid
indic
alveolarcapillari
membran
damag
eicosanoid
lipidderiv
small
molecul
may
serv
use
biomark
especi
vascular
physiolog
oxid
damag
inflamm
futur
studi
children
ard
advanc
genet
scienc
technolog
enabl
research
feasibl
use
nucleic
acidbas
biomark
assay
acut
ill
major
target
small
rna
molecul
microrna
mirna
due
abund
blood
bodi
fluid
well
rel
resist
degrad
may
util
biomark
mirna
predict
structur
variabl
express
pattern
depend
bodi
site
physiolog
condit
mirna
perform
import
function
role
cellular
function
abil
regul
translat
specif
gene
product
mrna
level
singl
mirna
speci
may
multipl
gene
target
anoth
notabl
featur
mirna
potenti
therapeut
target
due
abil
regul
antisens
version
antagomir
though
mani
mirna
identifi
possibl
contributor
marker
lung
diseas
clinic
data
human
ard
extrem
limit
fertil
area
studi
children
ard
addit
type
nonprotein
biomark
may
util
pediatr
lung
diseas
includ
sever
type
extracellular
complex
includ
circul
mp
also
known
microvesicl
cellular
exosom
neutrophil
extracellular
trap
net
mp
class
cellderiv
vesicl
develop
bud
membran
mani
differ
cell
type
rang
size
nm
may
carri
varieti
differ
content
includ
protein
lipid
nucleic
acid
wide
varieti
potenti
effect
lung
injuri
depend
origin
locat
content
mp
isol
blood
bal
fluid
adult
ard
patient
subtyp
base
cellular
origin
certain
subtyp
leukocytederiv
mp
demonstr
possibl
prognost
signific
mpbase
biomark
may
prove
use
futur
studi
children
ard
may
also
potenti
therapeut
agent
abl
ferri
payload
drug
substanc
specif
target
tissu
base
molecular
tropism
net
deriv
program
death
circul
neutrophil
compos
extrud
cellular
content
includ
nuclear
chromatin
histon
protein
variou
protein
net
antimicrobi
activ
propos
host
defens
mechan
net
detect
plasma
bal
patient
transfusionrel
acut
lung
injuri
trali
critic
ill
circul
extracellular
histon
major
protein
compon
net
directli
cytotox
elev
set
traumaassoci
lung
injuri
net
mp
extracellular
complex
repres
potenti
use
biomark
children
ard
sinc
initi
descript
ard
widespread
investig
pathobiolog
syndrom
well
better
way
care
victim
increas
use
molecular
techniqu
studi
ard
diseas
process
gain
great
deal
knowledg
relat
develop
progress
resolut
devast
condit
one
major
hope
applic
knowledg
character
subpopul
within
wide
regard
extrem
heterogen
diseas
may
lead
develop
specif
therapi
tailor
toward
pathophysiolog
chang
found
subpopul
preliminari
step
process
realiz
recent
descript
biomark
panel
ard
public
latent
class
analysi
two
ard
clinic
trial
calfe
et
al
describ
two
subphenotyp
hyperand
hypoinflammatori
differenti
clinic
respons
trial
intervent
find
base
analysi
clinic
characterist
multipl
biomark
hold
promis
subphenotyp
might
use
guid
design
futur
clinic
trial
target
high
vs
low
popul
asthma
though
clear
ard
subphenotyp
yet
identifi
pediatr
patient
would
seem
principl
could
reason
appli
also
import
recogn
inform
biomark
pard
may
provid
valu
term
abil
improv
risk
stratif
also
better
defin
pathophysiolog
heterogen
condit
better
risk
stratif
allow
welldesign
trial
pard
therapi
improv
prognost
famili
counterpoint
improv
understand
patholog
mechan
lead
pard
regul
resolut
may
form
base
develop
novel
therapi
new
type
biomark
nonprotein
nucleic
acidbas
biomark
potenti
rich
sourc
inform
remain
rel
untap
pediatr
popul
challeng
remain
especi
technic
aspect
isol
character
quantifi
nonprotein
biomark
larg
number
children
ard
howev
technolog
advanc
especi
realm
nucleic
acid
sequenc
polymeras
chain
reaction
pcr
base
method
dramat
reduc
price
process
time
assay
genet
materi
method
largescal
isol
lipid
vesiclebas
mp
yet
welldevelop
certainli
improv
come
year
nucleic
acid
lipid
vesicl
appeal
marker
potenti
therapeut
agent
potenti
act
tissu
biochem
pathwayspecif
mechan
may
increas
potenc
decreas
unwant
side
effect
nonprotein
biomark
thu
repres
signific
field
futur
research
pard
mani
remain
difficulti
pursuit
accur
use
biomarkerbas
model
pard
one
major
challeng
establish
widespread
use
common
diagnost
criteria
ard
children
though
consensu
criteria
avail
decad
adult
pediatricspecif
definit
ard
refer
pard
publish
definit
expand
upon
adult
berlin
definit
allow
criteria
clinic
relev
pediatr
unilater
radiograph
infiltr
puls
oximetrybas
oxygen
metric
also
util
oxygen
index
oi
wellvalid
pediatr
lung
diseas
risk
stratif
tool
definit
becom
wide
adopt
help
improv
compar
pediatr
studi
ard
especi
oi
reflect
fraction
inspir
oxygen
also
mean
airway
pressur
support
futur
studi
ard
biomark
children
therefor
strive
abid
definit
inde
mani
previous
identifi
biomark
ard
children
like
revalid
use
new
pard
criteria
definit
biomark
found
measur
bodi
fluid
tissu
therefor
measur
necessari
collect
biolog
sampl
societi
vulner
member
children
sensit
collect
larg
volum
sampl
adult
parent
often
wari
allow
sick
children
particip
clinic
research
fortun
recent
year
mani
improv
assay
technolog
allow
develop
multiplex
assay
measur
dozen
protein
biomark
singl
fluid
sampl
greatli
improv
inform
yield
limit
patient
popul
technolog
like
help
overcom
major
challeng
pard
research
overal
pauciti
data
howev
also
requir
concert
effort
toward
collabor
mani
research
institut
expand
avail
pool
data
system
incent
place
fund
promot
must
also
reexamin
support
collabor
research
addit
individu
project
research
group
pediatr
acut
lung
injuri
sepsi
investig
collabor
pediatr
critic
care
research
network
among
other
must
continu
expand
share
databas
biomark
data
facilit
new
insight
gener
hypothes
new
clinic
trial
larger
data
set
may
allow
improv
sensit
specif
well
expand
extern
valid
known
biomark
meaning
clinic
tool
score
could
develop
around
howev
order
make
use
larg
data
set
pediatr
research
need
embrac
grow
field
biomed
informat
largescal
inform
analysi
util
complex
algorithm
machin
learn
effici
detect
pattern
subpopul
would
otherwis
invis
convent
techniqu
howev
requir
dedic
resourc
data
access
best
suit
collabor
network
pard
biomark
yet
achiev
clinic
util
creatinin
wwwpalisiorg
wwwcpccrnorg
kidney
injuri
troponin
myocardi
infarct
largescal
collabor
data
analysi
chanc
success
grow
dramat
data
glean
biomark
test
may
offer
time
valuabl
diagnost
prognost
inform
avail
set
ard
especi
true
pediatr
medicin
invas
diagnost
procedur
bronchoscopi
biopsi
well
radiat
exposur
relat
diagnost
imag
limit
much
possibl
set
low
mortal
pard
biomark
panel
thereof
may
also
valuabl
therapeut
trial
clinic
physiolog
meaning
surrog
outcom
biomark
data
use
accur
diagnosi
guidanc
treatment
wide
vari
medic
condit
effort
expand
use
pard
continu
suffer
challeng
due
rel
low
incid
diseas
standard
diagnost
criteria
measur
techniqu
fund
limit
collabor
nation
institut
essenti
replic
initi
result
continu
innov
expand
applic
find
divers
pediatr
popul
dr
bo
conceiv
project
jointli
prepar
abstract
propos
dr
bo
draft
manuscript
dr
provid
subject
matter
guidanc
critic
review
revis
manuscript
author
approv
final
manuscript
prior
public
would
like
thank
dr
wannasiri
lapcharoensap
contribut
edit
critic
review
manuscript
work
fund
part
nih
grant
nhlbi
sapru
nhlbi
sapru
author
disclosur
relat
financi
interest
drug
devic
studi
discuss
herein
